Determinants of attained estradiol levels in response to oral estradiol plus progesterone therapy.
Intira SriprasertH N HodisB BernickS MirkinW J MackPublished in: Climacteric : the journal of the International Menopause Society (2020)
Adjusting for E2 dose and baseline E2 level, on-trial E2 levels were significantly associated with time since menopause, current smoking, and current alcohol use. Practitioners should consider these factors in individual women to achieve a desirable E2 level during HT.
Keyphrases
- estrogen receptor
- primary care
- polycystic ovary syndrome
- clinical trial
- study protocol
- phase iii
- smoking cessation
- postmenopausal women
- pregnancy outcomes
- stem cells
- phase ii
- type diabetes
- randomized controlled trial
- metabolic syndrome
- pregnant women
- skeletal muscle
- insulin resistance
- breast cancer risk
- open label
- cell therapy